X4 Pharmaceuticals Inc
NASDAQ:XFOR

Watchlist Manager
X4 Pharmaceuticals Inc Logo
X4 Pharmaceuticals Inc
NASDAQ:XFOR
Watchlist
Price: 3.91 USD 0.77% Market Closed
Market Cap: 341.9m USD

Operating Margin
X4 Pharmaceuticals Inc

-291.1%
Current
-3 060%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-291.1%
=
Operating Profit
-98.9m
/
Revenue
34m

Operating Margin Across Competitors

No Stocks Found

X4 Pharmaceuticals Inc
Glance View

Market Cap
341.9m USD
Industry
Biotechnology

X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company is headquartered in Boston, Massachusetts and currently employs 83 full-time employees. The company went IPO on 2017-11-16. The firm is focused on the research, development and commercialization of therapeutics for the treatment of rare diseases with an initial focus on the treatment of people with immune system dysfunction. Its lead product candidate, mavorixafor, is a small molecule inhibitor of the chemokine receptor CXCR4 and is being developed as a once-daily oral therapy. Its mavorixafor demonstrated ability to antagonize CXCR4 and improve the healthy maturation and trafficking of white blood cells (WBCs), which provides therapeutic benefit across a variety of diseases, including primary immunodeficiencies (PIDs) and certain types of cancer. Its mavorixafor is in a global Phase III clinical trial for the treatment of warts, hypogammaglobulinemia, infections and myelokathexis (WHIM) syndrome, a rare, inherited PID caused by genetic mutations in the CXCR4 receptor gene. Its product candidates include X4P-001, X4P-002 and X4P-003.

XFOR Intrinsic Value
2.81 USD
Overvaluation 28%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-291.1%
=
Operating Profit
-98.9m
/
Revenue
34m
What is the Operating Margin of X4 Pharmaceuticals Inc?

Based on X4 Pharmaceuticals Inc's most recent financial statements, the company has Operating Margin of -291.1%.

Back to Top